RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Australia Implementing Prior Approval for Minor Variations

Australia Implementing Prior Approval for Minor Variations

Posted 25 September 2012 | By Louise Zornoza

Australia's Therapeutic Goods Administration (TGA) has announced planned amendments to the regulatory requirements for making minor variations to registered prescription drugs.

Minor variations include any changes not requiring clinical, nonclinical or quality data to be submitted to regulators, and are typically submitted to TGA under what is known as the Streamlined Submission Process.

Under TGA's newly amended regulatory requirements, minor variations will be classified as either Safety-Related Requests (SRRs) or Self-Assessable Requests (SARs) for variations that are not safety related, and both will require prior TGA approval. 

There will be a three-month transition period, during which the TGA will: 

  • not strictly enforce the requirement for prior approval given that sponsors may already be in the process of preparing applications under current requirements; and 
  • will give priority to new submissions in the amended SAR format over those submitted under the current requirements.  

The TGA will be issuing guidance on the new regulatory process.


© 2022 Regulatory Affairs Professionals Society.